Autotac (Pharmaceuticals) is Drug Discovery in South Korea that focus on provider business. Founded in 2018. They cover business area such as provider, therapeutic, all disease, human, protein target decomposition platform technology, treatment, various rare and incurable disease, addition, viral infection, cancer, degenerative brain disease, amyloid disease, autoimmunity, coronavirus, autophagy-base target decomposition technology, disease substance.
2018
( 6 years old in 2024 )
Provider
-
5th floor, 254
Changgyeonggung-ro, Jongno-gu
Seoul
South Korea
Private
providertherapeuticall diseasehumanprotein target decomposition platform technologytreatmentvarious rare and incurable diseaseadditionviral infectioncancerdegenerative brain diseaseamyloid diseaseautoimmunitycoronavirusautophagy-base target decomposition technologydisease substance
* We use standard office opening hours in near Autotac (Pharmaceuticals)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Autotac (Pharmaceuticals) is Drug Discovery business from South Korea that founded in 2018 (6 years old in 2024), Autotac (Pharmaceuticals) business is focusing on Provider.
Autotac (Pharmaceuticals) headquarter office and corporate office address is located in 5th floor, 254 Changgyeonggung-ro, Jongno-gu Seoul South Korea.
Autotac (Pharmaceuticals) was founded in South Korea.
In 2024, Autotac (Pharmaceuticals) is currently focus on provider sector.
Above is snippet of Google Trends for "provider" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Autotac (Pharmaceuticals), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.